Colorectal Neoplasm

This retrospective study examines outcomes of 158 primary sporadic colorectal cancer patients who had undergone surgical resection and were treated with 5-fluorouracil based chemotherapy. Cytoplasmic … (full text at CIViC)

PMID 17590872 · Kato et al., 2007 · Open in CIViC

112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1α and ALD… (full text at CIViC)

PMID 24708484 · Sim et al., 2014 · Open in CIViC

While evidence from multiple clinical studies establishing a strong association between loss of function mutations in APC and response to 5-fluorouracil is lacking, some studies suggest APC mutations … (full text at CIViC)

PMID 19307944 · Chen et al., 2009 · Open in CIViC

G007-LK inhibits in vivo tumor growth in a subset of APC-mutant colorectal cancers xenograft models but may be limited by intestinal toxicity.

PMID 23539443 · Lau et al., 2013 · Open in CIViC

226 cetuximab-treated patients with colorectal cancer (CRC) were analyzed for mRNA expression (by qPCR) of EGFR and its ligands (EGF, TGFA, AREG and EREG). High AREG mRNA expression in KRAS wild type … (full text at CIViC)

PMID 23374602 · Pentheroudakis et al., 2013 · Open in CIViC

Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified… (full text at CIViC)

PMID 26867820 · Seligmann et al., 2016 · Open in CIViC

In an in vitro study, human colorectal cancer cell line HCT116 cell line was made to homozygously express ARID1A Q546* via adeno-associated virus-mediated somatic gene targeting. Compared to the paren… (full text at CIViC)

PMID 27364904 · Miller et al., 2016 · Open in CIViC

In this phase II basket trial (TAPUR), response to olaparib treatment was examined in four cohorts with ATM mutations. In the colorectal cancer cohort (27 evaluable patients) there was one PR and thre… (full text at CIViC)

PMID 41538762 · Carrizosa et al., 2026 · Open in CIViC

Fifty-nine (3.4%) of 1,751 patients with CRC harbored B2M mutations, with 84% (77 of 92) of the mutations predicted to be truncating. B2M mutations were significantly enriched in MSI-H CRCs, with 44 (… (full text at CIViC)

PMID 31008436 · Middha et al., 2019 · Open in CIViC

Loss of BARD1 function through the expression of a BARD1 splice variant, BARD1β, results in a more malignant phenotype with decreased RAD51 foci formation, reduced BRCA1 E3 ubiquitin ligase activity, … (full text at CIViC)

PMID 27197561 · Ozden et al., 2016 · Open in CIViC

Livin (BIRC7) overexpression in two colon cancer cell lines (RKO and SW620) increased resistance of these cells to cisplatin. siRNA knockdown of Livin rendered the cells more sensitive to cisplatin. T… (full text at CIViC)

PMID 23188704 · Ding et al., 2013 · Open in CIViC

Paired pre-treatment and post-progression tumor biopsies from BRAF-mutant CRC patients treated with RAF inhibitor combinations were analyzed. Alterations in MAPK pathway genes were found in resistant … (full text at CIViC)

PMID 25673644 · Ahronian et al., 2015 · Open in CIViC

In a study of 468 colorectal cancer samples, 407 patients had micro-satellite stable tumors and there was a statistically significantly better prognosis for APC WT patients relative to APC-mutated pat… (full text at CIViC)

PMID 27302369 · Schell et al., 2016 · Open in CIViC

In a multicenter pooled analysis of consecutive patients with non-V600 BRAF mutated metastatic colorectal cancer, the effects of anti-EGFR antibody therapy were analyzed. Non-V600 BRAF mutations were … (full text at CIViC)

PMID 31515458 · Yaeger et al., 2019 · Open in CIViC

In a multicenter pooled analysis of consecutive patients with non-V600 BRAF mutated metastatic colorectal cancer, the effects of anti-EGFR antibody therapy were analyzed. Non-V600 BRAF mutations were … (full text at CIViC)

PMID 31515458 · Yaeger et al., 2019 · Open in CIViC

Data from 117 patients with metastatic colorectal cancer (mCRC) harboring various BRAF mutations and 540 patients with mCRC harboring BRAF wild type were analyzed. BRAF mutation type was categorized t… (full text at CIViC)

PMID 30967421 · Schirripa et al., 2019 · Open in CIViC

In a study of 908 patients with colorectal cancer (CRC), 7 patients had BRAF D595G mutations and 589 patients were BRAF wild type. The survival rate of CRC patients at 3 years was significantly poorer… (full text at CIViC)

PMID 27404270 · Amaki-Takao et al., 2016 · Open in CIViC

In a study of 908 patients with colorectal cancer, 7 patients had BRAF (D594G) mutations and 45 patients had BRAF (V600E) mutations. Overall clinicopathological implications of BRAF V600E and D594G mu… (full text at CIViC)

PMID 27404270 · Amaki-Takao et al., 2016 · Open in CIViC

The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 pati… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patients harboring BRAF G466A (n=1), G469A (n=2), D594G (n=1), or V600E (n=2) mutations were reported to b… (full text at CIViC)

PMID 26989027 · Hsu et al., 2016 · Open in CIViC

In the study with a tumour from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumour regression. And in tumour cell… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumor regression. And in tumor cells o… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patients harboring BRAF G466A (n=1), G469A (n=2), D594G (n=1), or V600E (n=2) mutations were reported to b… (full text at CIViC)

PMID 26989027 · Hsu et al., 2016 · Open in CIViC

Data from 117 patients with metastatic colorectal cancer (mCRC) harboring various BRAF mutations and 540 patients with mCRC harboring BRAF wild type were analyzed. BRAF mutation type was categorized t… (full text at CIViC)

PMID 30967421 · Schirripa et al., 2019 · Open in CIViC

Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell-growth and impact on signalling was measured: ERK signalling by wester… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

In an in vitro study, an NCI-H508 cell line expressing BRAF G596R demonstrated insensitivity to vemurafenib treatment compared to HT29 cells expressing BRAF V600E (a known vemurafenib sensitizing muta… (full text at CIViC)

PMID 22180495 · Yang et al., 2012 · Open in CIViC

Data from 117 patients with metastatic colorectal cancer (mCRC) harboring various BRAF mutations and 540 patients with mCRC harboring BRAF wild type were analyzed. BRAF mutation type was categorized t… (full text at CIViC)

PMID 30967421 · Schirripa et al., 2019 · Open in CIViC

Data from 117 patients with metastatic colorectal cancer (mCRC) harboring various BRAF mutations and 540 patients with mCRC harboring BRAF wild type were analyzed. BRAF mutation type was categorized t… (full text at CIViC)

PMID 30967421 · Schirripa et al., 2019 · Open in CIViC

In the Medical Research Council (MRC) COIN trial, ISRCTN27286448, patients who presented with advanced colorectal cancer were randomly assigned to chemotherapy (oxaliplatin and fluoropyrimidine; arm A… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

A meta analysis was performed using data from 21 published studies (n = 9885 patients) to assess prognostic value of BRAF mutations in colorectal cancer. When evaluating 14 studies (n = 7778 patients)… (full text at CIViC)

PMID 24112392 · Clancy et al., 2013 · Open in CIViC

This study of 9,643 patients characterized clinical implications of non-V600 BRAF mutations in metastatic CRC. Of the patients with metastatic CRC that underwent NGS testing, 208 patients had non-V60… (full text at CIViC)

PMID 28486044 · Jones et al., 2017 · Open in CIViC

Patients with BRAF-V600 mutated cancers were identified (n=122) and subsequently underwent targeted therapy. 27 patients with colorectal cancer were treated with vemurafenib and cetuximab (N=24 with B… (full text at CIViC)

PMID 26287849 · Hyman et al., 2015 · Open in CIViC

In clinical trial NCT01072175, 43 patients with BRAF V600 metastatic colorectal cancer (CRC) received mutant BRAF inhibitor dabrafenib and MEK inhibitor trametinib. Only 12% of patients showed partia… (full text at CIViC)

PMID 26392102 · Corcoran et al., 2015 · Open in CIViC